APEXIGEN INC (APGN) Forecast, Price Target & Analyst Ratings
NASDAQ:APGN • US03759B1026
0.3851 USD
+0.03 (+8.48%)
At close: Aug 22, 2023
0.3807 USD
0 (-1.14%)
After Hours: 8/22/2023, 8:00:00 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for APEXIGEN INC (APGN).
Forecast Snapshot
Consensus Price Target
$0.65
+ 69.51% Upside
Next Earnings Forecast
Release DateN/A
PeriodQ3 / 2023
EPS Estimate-$0.19
Revenue Estimate1.53M
ChartMill Buy Consensus
43.33%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$0.65
Upside
+ 69.51%
From current price of $0.39 to mean target of $0.65, Based on 6 analyst forecasts
Low
$0.65
Median
$0.65
High
$0.67
Price Target Revisions
1 Month
N/A
3 Months
N/A
Price Target Summary
6 Wall Street analysts provided a forecast for the next 12 months for APGN. The average price target is 0.65 USD. This implies a price increase of 69.51% is expected in the next year compared to the current price of 0.3851.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
43.33%
APGN was analyzed by 6 analysts. The buy percentage consensus is at 43. So analysts seem to be rather negative about APGN.
In the last month the buy percentage fell by 5 points. So the trust of analysts is decreasing.
APGN was analyzed by 6 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2023-05-26 | EF Hutton | Reiterate | Hold -> Hold |
| 2023-05-24 | EF Hutton | Downgrade | Buy -> Hold |
| 2023-05-16 | EF Hutton | Maintains | Buy -> Buy |
| 2023-01-24 | Roth Capital | Reiterate | Buy |
| 2023-01-05 | EF Hutton | Initiate | Buy |
Next Earnings Forecast Details
Next Earnings Details
Release DateN/A
PeriodQ3 / 2023
EPS Estimate-$0.19
Revenue Estimate1.53M
Revenue Q2QN/A
EPS Q2Q52.73%
Number of Analysts3
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
N/A
EPS (3 Months)
N/A
Next Earnings Summary
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A 56.52% | N/A 11.11% | N/A 623.19% | N/A 62.82% | N/A 46.09% | N/A 82.56% | N/A -21.19% | |
| EBITDA YoY % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | N/A | N/A 50.65% | N/A -10.18% | N/A -54.08% | N/A -29.86% | N/A -41.23% | N/A -29.73% | N/A 27.44% | N/A 308.04% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A 70.12% | N/A 47.00% | N/A 1.89% | N/A -65.38% | N/A -3.49% | N/A -14.61% | N/A 31.37% | N/A |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q3 / 23 | Q4 / 23 | |
|---|---|---|
| EPS Q2Q % growth | -0.19 52.73% | -0.08 75.27% |
| Revenue Q2Q % growth | 1.53M | 1.53M |
| EBITDA Q2Q % growth | N/A | N/A |
| EBIT Q2Q % growth | -4.794M 43.37% | -4.896M 42.80% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
N/A
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
APEXIGEN INC / APGN Forecast FAQ
What is the average price target for APEXIGEN INC (APGN) stock?
6 analysts have analysed APGN and the average price target is 0.65 USD. This implies a price increase of 69.51% is expected in the next year compared to the current price of 0.3851.
What are the consensus estimates for APGN stock next earnings?
The consensus EPS estimate for the next earnings of APEXIGEN INC (APGN) is -0.19 USD and the consensus revenue estimate is 1.53M USD.